AMRX
HEALTHCAREAmneal Pharmaceuticals Inc - Class A
$13.62+0.21 (+1.57%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AMRX Today?
No stock-specific AI insight has been generated for AMRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.02$15.42
$13.62
Fundamentals
Market Cap$4.4B
P/E Ratio62.4
EPS$0.22
Dividend Yield—
Dividend / Share—
ROE-8.8%
Profit Margin0.0%
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding319.0M
AMRX News
21 articles- Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)Yahoo Finance·May 8, 2026
- Amneal Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Amneal Pharmaceuticals Kashiv Deal Puts Biosimilar Growth And Valuation In FocusYahoo Finance·May 6, 2026
- Do Options Traders Know Something About Amneal Stock We Don't?Yahoo Finance·May 5, 2026
- How The Amneal Pharmaceuticals (AMRX) Story Is Shifting Around The New US$17 Price TargetYahoo Finance·May 5, 2026
- 1 Value Stock to Target This Week and 2 Facing ChallengesYahoo Finance·May 4, 2026
- UBS Initiates Coverage of Amneal Pharmaceuticals (AMRX) With a Bullish OutlookYahoo Finance·May 1, 2026
- Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"Yahoo Finance·Apr 29, 2026
- Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?Yahoo Finance·Apr 29, 2026
- Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?Yahoo Finance·Apr 29, 2026
- Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?Yahoo Finance·Apr 29, 2026
- Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Returns And Recent Share Price CooldownYahoo Finance·Apr 25, 2026
- Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar PushMarketbeat·Apr 24, 2026
- Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·Apr 23, 2026
- AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary ResultsYahoo Finance·Apr 23, 2026
- Amneal Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·Apr 22, 2026
- Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass EstimatesYahoo Finance·Apr 22, 2026
- Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar LeaderYahoo Finance·Apr 22, 2026
- Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone GuidanceYahoo Finance·Apr 22, 2026
- Amneal’s Parkinson’s And Respiratory Moves Shift Focus To Complex TherapiesYahoo Finance·Apr 21, 2026
- Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.GlobeNewswire Inc.·Apr 14, 2026
All 21 articles loaded
Price Data
Open$13.60
Previous Close$13.41
Day High$13.70
Day Low$13.45
52 Week High$15.42
52 Week Low$7.02
52-Week Range
$7.02$15.42
$13.62
Fundamentals
Market Cap$4.4B
P/E Ratio62.4
EPS$0.22
Dividend Yield—
Dividend / Share—
ROE-8.8%
Profit Margin0.0%
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding319.0M
About Amneal Pharmaceuticals Inc - Class A
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—